|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 22:06
|
Glaukos Announces Second Quarter 2025 Financial Results (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include:
Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis.
Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year.
U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year.
Gross margin of approximately 78% and non-GAAP gross margin of approximately 83% in Q2 2025.
Raised 2025 net sales guidance to $480 million to $486 million, compared to $475 million to $485 million previously.
“Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plan...
|
|
|
|
|
09.07.25 - 13:09
|
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 (Business Wire)
|
|
|
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025.
A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the company's website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel th...
|
|
|
08.07.25 - 14:06
|
FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors (Business Wire)
|
|
|
FUKUOKA, Japan & NEW YORK--(BUSINESS WIRE)--FELIQS Corporation (“FELIQS”), a biotechnology company developing first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases, today announced the today announced the appointment of two distinguished industry leaders, Gregory Kunst and Joe Zenkus, to its Board of Directors. The appointments follow a recently secured investment aimed at accelerating FELIQS's clinical programs.
Gregory Kunst brings over 20 years of leadership experience in the biopharmaceutical industry, having served as CEO of Aurion Biotech and held senior roles at Glaukos Corporation and other medical innovation companies. His deep operational expertise in corporate strategy, global product development, and commercialization will be instrumental as FELIQS advances its pipeline.
Joe Zenkus brings executive leadership experience and a strong perspective on rare disease drug development, commercialization and strategy based on his large pharma an...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.25 - 22:09
|
Glaukos Announces First Quarter 2025 Financial Results (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include:
Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis.
Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year.
U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year.
Gross margin of approximately 77% and non-GAAP gross margin of approximately 82% in Q1 2025.
Reaffirmed 2025 net sales guidance of $475 million to $485 million.
“Our record first quarter results reflect a strong start to the year and sustained growth acceleration in our business driven by successful global execution of our key strategic plans,” said Thomas Burn...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
